Innovation

Development Pipeline

Development Pipeline

We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need. In clinical development we are currently advancing more than 40 projects that we review regularly so that we can give priority to the most promising programs.

Pipeline Overview

Here you can find an overview on our development pipeline.

uebersichtsgrafik-der-phasen

 

Therapeutic Areas:

Oncology

Cardiovascular Diseases

Women's Health

Others

 

The following table lists a selection of major Pharma portfolio projects in clinical Phase I to III development, including the respective indication, therapeutic area and development status.

Therapeutic Area Phase Program (mode-of-action) Indication NME1/
LCM2
Oncology III Darolutamide (AR Inhibitor) Prostate Cancer (mHSPC) LCM
Oncology III Darolutamide (AR Inhibitor) Adjuvant Prostate Cancer LCM
Oncology III Copanlisib (PI3K Inhibitor) Non-Hodgkin Lymphoma LCM
Oncology III Regorafenib (multi-Kinase Inhibitor) Glioblastoma LCM
Cardiovascular Diseases III Finerenone (MR Antagonist) Heart Failure (HFmr/pEF) LCM
Cardiovascular Diseases III Finerenone (MR Antagonist) Non-diabetic CKD LCM
Cardiovascular Diseases III Vericiguat (sGC Stimulator) Heart Failure (HFrEF) LCM
Women's Health III Elinzanetant (Neurokinin-1,3 Rec Antag.) Vasomotor Symptoms NME
Others III Aflibercept High Dose Diabetic Macular Edema (DME) LCM
Others III Aflibercept High Dose Neovasc. Age-rel. Macular Degen. (nAMD) LCM
Oncology II Regorafenib (combi Nivolumab) Solid tumors (recurrent or metastatic) LCM
Oncology II Regorafenib (combi Pembrolizumab) Hepatocellular Carcinoma (HCC) LCM
Cardiovascular Diseases II Asundexian (FXIa Inhibitor) Stroke Prevention in Atrial Fibrillation
Insight Story Link
NME
Cardiovascular Diseases II Asundexian (FXIa Inhibitor) 2 Stroke Prevention
Insight Story Link
NME
Cardiovascular Diseases II Asundexian (FXIa Inhibitor) Major Adverse Cardiac Events Prevention
Insight Story Link
NME
Cardiovascular Diseases II Fesomersen (FXI-LICA) Thrombosis Prevention in ESRD
Insight Story Link
NME
Cardiovascular Diseases II Osocimab (anti-FXIa Antibody) Thrombosis Prevention in ESRD
Insight Story Link
NME
Cardiovascular Diseases II Runcaciguat (sGC Activator) Chronic Kidney Disease (CKD) NME
Others II Runcaciguat (sGC Activator) Non-prolif. Diabetic Retinopathy (NPDR) NME
Others II Adrenomedullin Pegol (PEG-ADM) Acute Resp. Distress Syn. (ARDS) NME
Others II BDKRB1 Receptor Antagonist Neuropathic Pain NME
Others II High Relaxivity Contrast Agent (HRCA) Magnetic Resonance Imaging NME
Oncology I Elimusertib (ATR Inhibitor) Cancer NME
Oncology I SLFN12 Complex-Inducer Cancer NME
Oncology I mEGFR Inhibitor Cancer NME
Oncology I 227Th-Pelgifatamab Corixetan (PSMA-Targeted Thorium Conjugate) Cancer NME
Oncology I HER2-TTC (HER2-Targeted Thorium Conjugate) Cancer
Insight Story Link
NME
Oncology I Bapotulimab (ILDR2 fb Antibody) Cancer NME
Oncology I AhR Inhibitor Cancer
Insight Story Link
NME
Oncology I ATA2271 (Mesothelin CAR-T Cell Therapy) Cancer NME
Cardiovascular Diseases I Congestive Heart Failure Gene Therapy Congestive Heart Failure NME
Cardiovascular Diseases I Mosliciguat (sGC Activator) Cardiovascular Diseases NME
Cardiovascular Diseases I Enuvaptan (Vasopressin V1a Receptor Antagonist) Cardiovascular Diseases NME
Cardiovascular Diseases I sGC Activator 4 Cardiovascular Diseases NME
Women's Health I P2X4 Antagonist Endometriosis NME
Women's Health I BDKRB1 Receptor Antagonist Endometriosis NME
Others I Peboctocogene Camaparvovec (FVIII Gene Therapy) Hemophilia A
Insight Story Link
NME
Others I Pompe Disease Gene Therapy Pompe Disease NME
Others I Parkinson‘s Disease Gene Therapy Parkinson's Disease NME
Others I Parkinson’s Disease Cell Therapy Parkinson's Disease NME
Others I sGC Activator 3   NME
Others I ADRA2C Antagonist   NME
Others I Zabedosertib (IRAK4 Inhibitor)   NME

1 NME (New Molecular Entity)
2 LCM (Life Cycle Management)

 

Dr. Julia Schulze
R&D and Science - Research
Pamela Cohen
R&D and Science - Development